ArticleO&G open2026
Addressing Obstetric and Gynecologic Needs in Thalassemia.
Abstract read
In one paragraph
Article in O&G open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Evangelia VlachodimitropoulouDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Marina BaldiniDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Hanny Al-SamkariDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Maria Domenica CappelliniDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Thomas D CoatesDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Kevin H M KuoDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Sujit ShethDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Ali T TaherDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Vip ViprakasitDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Khaled M MusallamDepartment of Obstetrics and Gynaecology, King's College Hospital, London, UK; Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Hematology Section, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California; Division of Hematology, University of Toronto, Toronto, Ontario, Canada; Scarborough Health Network, Scarborough, Ontario, Canada; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; and Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalassemia represents a spectrum of rare, inherited blood disorders associated with a range of disease- and treatment-related complications. Thalassemia can have a significant effect on the female reproductive system, and obstetrics and gynecology specialists have a key role to play in managing the disease as part of a multidisciplinary team. Here, we review the role of obstetrics and gynecology specialists in thalassemia from puberty to pregnancy and postnatal support, including diagnosis and management of complications, supporting patients through pubertal and fertility issues and the risks associated with pregnancy.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.